Pazopanib together with 6-8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma.

ABSTRACT:

Background

The aim of the study was to investigate the temporary combination of anti-PD-1 plus targeted therapy followed by single targeted therapy in advanced renal cell carcinoma (RCC) as second-line therapy.

Methods

A total of 17 patients from Fudan University Shanghai Cancer Center (FUSCC) with advanced clear cell RCC were enrolled. They were treated with sunitinib (50 mg/day; 2 weeks on and 1 weeks off) as first-line therapy. After progression of the disease, sintilimab (200 mg iv/q3w) in combination with pazopanib (800 mg/day) were used. After 6-8 cycles of immunotherapy, patients were treated with pazopanib only. Cox proportional hazards models was used to evaluate the risk factors.

Results

Three patients reached partial response (PR) after second-line treatmen

SUBMITTER: Lu X 

PROVIDER: S-EPMC8185682 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature